Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Ludwig Enterprises Inc (ID) LUDG

Healthcare Medical Care Medical Devices
Ludwig Enterprises, Inc. operates as a genomic technology and health related company in the United States. The company engages in the developing of products that use inflammatory genetic markers to assess the occurrence of inflammation and inflammation related diseases, as well as monitor treatment responses. It also provides Revealia for Life Home Test Kits, that identify the potential to develop chronic inflammatory diseases, such as cancer and heart disease. In addition, the company develop a medical machine learning artificial intelligence technology that uses mRNA inflammatory language to capture an inflammatory snapshot of disease and the body’s response to treatment. Ludwig Enterprises, Inc. was incorporated in 2006 and is based in Miami, Florida.


OTCID:LUDG - Post by User

Ludwig Enterprises Inc (ID)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
  • averagepenniesX
Post by averagepennieson Feb 02, 2024 8:57am
81 Views
Post# 35859029

Ludwig Enterprises mRNA Bladder Cancer Study to be Launched

Ludwig Enterprises mRNA Bladder Cancer Study to be Launched

SPARKS, NV / ACCESSWIRE / January 31, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased to announce that the company has received Continuing Review Approval on its planned clinical study from Advarra IRB, Columbia, MD. Ludwig clinical study LL301 is titled: "Using Measurements of mRNA and Elisa- based Cytokine/Protein Indices to Evaluate Pre- and Post-Diagnosis and Treatment Response of Patients with Urothelial Carcinoma of the Bladder".

Marvin S. Hausman MD, CEO, stated: "We have looked forward to the launch of this study and are also pleased to announce that this research and potential breakthrough genetic results in BCG treatment of bladder cancer are covered in a filed international patent application. A personalized patient genetic index will be created to show the presence of bladder cancer as well as evaluate patient response to BCG immunotherapy."

https://www.accesswire.com/829541/ludwig-enterprises-mrna-bladder-cancer-study-to-be-launched

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities